Patent: 10,391,154
✉ Email this page to a colleague
Summary for Patent: 10,391,154
| Title: | Compositions and methods for treating or ameliorating fibrosis, systemic sclerosis and scleroderma |
| Abstract: | Provided are Adenosine Deaminase (ADA), or a polypeptides or peptides having an ADA activity, or an ADA conjugate, pharmaceutical compositions and formulations, products of manufacture and kits, and methods containing them for the prevention and treatment of a scleroderma-associated vasculopathy, in particular proliferative obliterative vasculopathy, progressive obliterative vasculopathy or an idiopathic obliterative vasculopathy and/or preventing or decreasing the progression of scleroderma, wherein optionally the scleroderma comprises a local scleroderma or a diffuse, or a systemic scleroderma. |
| Inventor(s): | Schreiber; Brian Dean (Oshkosh, WI), Fornasini; Gianfranco (Bethesda, MD), Soukhareva; Nadejda (Derwood, MD), Ramamurthy; Santosh Kumar (Columbia, MD) |
| Assignee: | LEADIANT BIOSCIENCES LTD. (London, GB) |
| Application Number: | 16/037,795 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,391,154
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Leadiant Biosciences, Inc | ADAGEN | pegademase bovine | Injection | 019818 | 03/21/1990 | ⤷ Try a Trial | 2037-07-19 |
| Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2037-07-19 |
| Genentech, Inc. | RITUXAN HYCELA | rituximab and hyaluronidase human | Injection | 761064 | 06/22/2017 | ⤷ Try a Trial | 2037-07-19 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
